Free Trial

Fennec Pharmaceuticals Q4 2023 Earnings Report

Fennec Pharmaceuticals logo
$5.54 -0.09 (-1.60%)
As of 01/17/2025 04:00 PM Eastern

Fennec Pharmaceuticals EPS Results

Actual EPS
-$0.10
Consensus EPS
$0.02
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A

Fennec Pharmaceuticals Revenue Results

Actual Revenue
$9.74 million
Expected Revenue
$9.47 million
Beat/Miss
Beat by +$270.00 thousand
YoY Revenue Growth
N/A

Fennec Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Fennec Pharmaceuticals Earnings Headlines

Fennec announces Pedmarqsi positive recommendation by NICE
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
See More Fennec Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fennec Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fennec Pharmaceuticals and other key companies, straight to your email.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals (NASDAQ:FENC)., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

View Fennec Pharmaceuticals Profile

More Earnings Resources from MarketBeat